These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27535291)

  • 61. Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
    Mulligan SP; Ward CM; Whalley D; Hilmer SN
    Br J Haematol; 2016 Nov; 175(3):359-364. PubMed ID: 27611114
    [No Abstract]   [Full Text] [Related]  

  • 62. Key Molecular Drivers of Chronic Lymphocytic Leukemia.
    Alsagaby SA; Brennan P; Pepper C
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):593-606. PubMed ID: 27601002
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
    Khouri IF; Sui D; Jabbour EJ; Samuels BI; Turturro F; Alatrash G; Anderlini P; Ahmed S; Oran B; Ciurea SO; Marin D; Olson A; Patel KK; Popat UR; Ledesma C; Kadia TM; Ferrajoli A; Burger JA; Jorgensen JL; Medeiros LJ; Bassett RL; Gulbis AM
    Bone Marrow Transplant; 2017 Jan; 52(1):28-33. PubMed ID: 27595282
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
    S Soderquist R; Eastman A
    Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Hansson L; Asklid A; Diels J; Eketorp-Sylvan S; Repits J; Søltoft F; Jäger U; Österborg A
    Ann Hematol; 2017 Oct; 96(10):1681-1691. PubMed ID: 28762081
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
    Singh M; Mealing S; Baculea S; Cote S; Whelan J
    J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?
    Tees MT; Flinn IW
    Curr Treat Options Oncol; 2017 Mar; 18(3):16. PubMed ID: 28286923
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Roskoski R
    Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
    Nguyen-Khac F; Borie C; Callet-Bauchu E; Eclache V; Struski S
    Ann Biol Clin (Paris); 2016 Oct; 74(5):561-567. PubMed ID: 27628190
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia.
    Herishanu Y; Polliack A; Shenhar-Tsarfaty S; Weinberger R; Gelman R; Ziv-Baran T; Zeltser D; Shapira I; Berliner S; Rogowski O
    Ann Med; 2017 Feb; 49(1):75-82. PubMed ID: 27595291
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).
    Jiang Y; Chen HC; Su X; Thompson PA; Liu X; Do KA; Wierda W; Keating MJ; Plunkett W
    Blood Cancer J; 2016 Sep; 6(9):e465. PubMed ID: 27588518
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights.
    Ciccone M; Calin GA
    Microrna; 2016; 5(2):106-112. PubMed ID: 27568792
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Symptomatic Hypercalcemia in a Patient with B-cell Chronic Lymphocytic Leukemia - A Case Report and Review of the Literature.
    Koutroumpakis E; Lobe M; McCarthy L; Mehdi S
    In Vivo; 2016 09-10; 30(5):691-4. PubMed ID: 27566092
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Frequency of monoclonal B-cell lymphocytosis in relatives of patients with chronic lymphocytic leukemia.
    Villegas Gracia R; Franco Alzate C; Rendón Henao J; Torres Hernández JD; Jaramillo Arbelaez PE
    Colomb Med (Cali); 2016 Jun; 47(2):81-6. PubMed ID: 27546929
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
    Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
    Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.
    Haerzschel A; Catusse J; Hutterer E; Paunovic M; Zirlik K; Eibel H; Krenn PW; Hartmann TN; Burger M
    Ann Hematol; 2016 Dec; 95(12):1979-1988. PubMed ID: 27542958
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
    Beck J; Schwarzer A; Gläser D; Mügge LO; Uhlig J; Heyn S; Kragl B; Mohren M; Hoffmann FA; Lange T; Schliwa T; Zehrfeld T; Becker C; Kreibich U; Winkelmann C; Edelmann T; Andrea M; Bill M; Jentzsch M; Schwind S; Niederwieser D; Pönisch W
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2545-2553. PubMed ID: 28828689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.